STRUCTURE THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.32 USD | +5.33% |
|
+6.80% | -5.99% |
| 21/05 | JPMorgan Starts Structure Therapeutics With Overweight Rating | MT |
| 09/05 | Structure Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 1,991 | 1,786 | - | - |
| Enterprise Value (EV) 1 | 1,991 | 1,459 | 1,631 | 1,498 |
| P/E ratio | -50.3 x | -43.1 x | -34.5 x | -23.8 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 80.4 x | - |
| EV / Revenue | - | - | 73.4 x | - |
| EV / EBITDA | - | -8.98 x | -9.03 x | -6.88 x |
| EV / FCF | - | -7.85 x | -8.96 x | -6.27 x |
| FCF Yield | - | -12.7% | -11.2% | -16% |
| Price to Book | - | 5.81 x | 12.8 x | 4.59 x |
| Nbr of stocks (in thousands) | 48,855 | 46,619 | - | - |
| Reference price 2 | 40.76 | 38.32 | 38.32 | 38.32 |
| Announcement Date | 08/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 22.22 | - |
| EBITDA 1 | - | - | - | -162.4 | -180.6 | -217.9 |
| EBIT 1 | - | -52.56 | -102.8 | -156.2 | -211.8 | -258.5 |
| Operating Margin | - | - | - | - | -953.12% | - |
| Earnings before Tax (EBT) 1 | - | -51.3 | -89.38 | -137.2 | -197.7 | -240 |
| Net income 1 | -38.05 | -52.84 | -89.62 | -133.6 | -156.7 | -227 |
| Net margin | - | - | - | - | -705.12% | - |
| EPS 2 | -5.380 | -5.510 | -0.8100 | -0.8900 | -1.110 | -1.608 |
| Free Cash Flow 1 | - | -51.48 | - | -186 | -182 | -239 |
| FCF margin | - | - | - | - | -819% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 12/01/23 | 30/03/23 | 08/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | - | -32 | -47 | -52 | - | - |
| EBIT 1 | -12.96 | -19.65 | -25.99 | -26.14 | -30.99 | -32.02 | -35.88 | -41.59 | -50.65 | -40.84 | -43.4 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -12.06 | -17.95 | -23.16 | -23.46 | -24.82 | -26.01 | -32.37 | -38.69 | -42.45 | -40.84 | -43.4 |
| Net income 1 | -11.88 | -17.98 | -23.28 | -23.86 | -24.5 | -26.04 | -31.62 | -36.01 | -39.27 | -40.84 | -43.4 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -1.170 | -0.2500 | -0.2000 | -0.2100 | -0.1600 | -0.1900 | -0.2233 | -0.2317 | -0.2450 | -0.2600 | -0.2900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 30/03/23 | 11/05/23 | 10/08/23 | 14/11/23 | 08/03/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 327 | 156 | 288 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -51.5 | - | -186 | -182 | -239 |
| ROE (net income / shareholders' equity) | - | - | - | -41.5% | -81.5% | -75.8% |
| ROA (Net income/ Total Assets) | - | - | - | -37.8% | -67.3% | -64% |
| Assets 1 | - | - | - | 353.6 | 232.7 | 354.9 |
| Book Value Per Share 2 | - | - | - | 6.600 | 2.990 | 8.340 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | - | 3 | 1.5 | 1.5 |
| Capex / Sales | - | - | - | - | 6.75% | - |
| Announcement Date | 12/01/23 | 30/03/23 | 08/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
38.32
USD
Average target price
75.7
USD
Spread / Average Target
+97.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.99% | 1.79B | |
| +10.79% | 116B | |
| +11.65% | 106B | |
| -6.20% | 23.89B | |
| -3.41% | 21.58B | |
| -11.23% | 18.96B | |
| -40.50% | 16.96B | |
| -13.41% | 16.33B | |
| +6.64% | 14.14B | |
| +31.84% | 12.02B |
- Stock Market
- Equities
- GPCR Stock
- Financials Structure Therapeutics Inc.
